April 15, 2020 — Crinetics has raised $100 million via public offering of 7.2 million shares of its stock to fund research for the treatment of rare diseases such as acromegaly, Cushing’s disease, congenital hyperinsulinism, and congenital adrenal hyperplasia. Read the full article on Global Genes – Allies in Rare Disease.